Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al.. Real-world effectiveness of Ketamine in treatment-resistant depression: a systematic review and meta-analysis. J Psychiatr Res. (2022) 151:693–709. doi: 10.1016/j.jpsychires.2022.04.037,

Amit Anand, M.D., Sanjay J. Mathew, M.D., Gerard Sanacora, M.D., Ph.D., James W. Murrough, M.D., Ph.D., Fernando S. Goes, M.D., Murat Altinay, M.D., Amy S. Aloysi, M.D., Ali A. Asghar-Ali, M.D., Brian S. Barnett, M.D., Lee C. Chang, M.D., Katherine A. Collins, M.S.W., Ph.D., Sara Costi, M.D., et al . Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression, New England Journal of Medicine, Vol 388, 25, 2023.
Asian Journal of Psychiatry, Volume 86, 2023.
CADTH Health Technology Review. Ketamine for Adults with Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update.

Kew BM, Porter RJ, Douglas KM, Glue P, Mentzel CL, Beaglehole B. Ketamine and psychotherapy for treating psychiatric disorders: systematic review. BJPsych Open. 2023 May 2; 9 (3): e79. doi: 10.1192/bjo.2023.53. PMID: 37128856; PMCID: PMC10228275.
Psychedelic Support, (2023). Ketamine Treatment Guide for Mental Health.

Saswinder Kaur, Chirag Parmar, Vikas Gaur, Ajay Chauhan, Chittaranjan Andrade,
The efficacy of oral ketamine in severely depressed patients at high risk of suicide,

Swainson J, Klassen LJ, Brennan S, Chokka P, Katzman MA, Tanguay RL, Khullar A. Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs. 2022 Mar;36(3):239-251. doi: 10.1007/s40263-022-00897-2. Epub 2022 Feb 14. PMID: 35165841; PMCID: PMC8853036.

Meta Research

Chubbs B, Wang J, Archer S, Chrenek C, Khullar A, Wolowyk M, Swainson J. A survey of drug liking and cravings in clients using sublingual or intranasal ketamine for treatment-resistant depression: A preliminary evaluation of real-world addictive potential. Front Psychiatry. 2022 Nov 17;13:1016439. doi: 10.3389/fpsyt.2022.1016439. PMID: 36465297; PMCID: PMC9714431.

Johansson, Andreas (2023): The reemergence of a psychiatric paradigm: A systematic review and meta-analysis of the efficacy of MDMA-assisted and Psilocybin-assisted psychotherapy for PTSD and MDD.

Romeo B, Karila L, Martelli C, Benyamina A. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. J Psychopharmacol. 2020 Oct;34(10):1079-1085. doi: 10.1177/0269881120919957. Epub 2020 May 25. PMID: 32448048


Artin H, Zisook S, Ramanathan D. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatry. 2021 Jun 19;11(6):201-214. doi: 10.5498/wjp.v11.i6.201. PMID: 34168967; PMCID: PMC8209538.

Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953–962. doi:10.1001/jamapsychiatry.2022.2096

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.

Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022 Feb;36(2):151-158. doi: 10.1177/02698811211073759. PMID: 35166158; PMCID: PMC8864328.
Psychedelic Support (2023). Psilocybin Assisted Therapy Guide.


Frontiers in Psychiatry (2024): MDMA-Assisted Therapy for Treatment of PTSD and Beyond: A collection of scholarly research.

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29, 2473–2480 (2023).

Premise, promise and challenges of MDMA assisted therapy for PTSD. Eur Neuropsychopharmacol. 2023 May;70:19-20. doi: 10.1016/j.euroneuro.2023.02.002. Epub 2023 Feb 15. PMID: 36806884; PMCID: PMC9930690.

Psychedelic Support (2023). MDMA-Assisted Therapy Guide.

Riaz K, Suneel S, Hamza Bin Abdul Malik M, Kashif T, Ullah I, Waris A, Di Nicola M, Mazza M, Sani G, Martinotti G, De Berardis D. MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence.Diseases. 2023 Nov 3;11(4):159. Doi 10.3390/diseases11040159. PMID: 37987270; PMCID: PMC10660711.